UnitedHealth's (UNH) Business Unit Collaborates With Merck
Zacks Investment Research | May 25, 2017 10:20PM ET
UnitedHealth Group, Inc.’s (NYSE:UNH) information and technology-enabled health services business “Optum” recently announced its collaboration with Merck & Co. Inc (NYSE:MRK) . The companies have primarily joined forces to develop and simulate the performance of contractual reimbursement models in which payment for prescription drugs is closely related to patient health outcomes.
Optum has carved a niche in terms of its expertise in pharmaceutical contracting, health economics and outcomes research, actuarial analytics, and health policy and regulation. Merck, on the other hand, boasts data science and outcomes research expertise, and a deep understanding of the pharmaceuticals marketplace. In addition, Merck’s vast experience of working with large private and public customers to create flexible pricing models across multiple therapy areas should help Optum cater to the needs of its customers more efficiently.
We note that Optum regularly upgrades its products and services through several partnerships and collaborations, which have resulted in UnitedHealth’s technological advancement on every front. Shareholders’ optimism about UnitedHealth’s digitalizing initiatives is clearly reflected in the company’s share price movement. In the last one year, the stock has gained 33%, slightly underperforming the Zacks categorized Health Maintenance Organization (HMO).
Through a shared “Learning Laboratory,” the companies are expected to study value-based and pay-for-performance models or Outcomes-Based Risk Sharing Agreements (“OBRSA”). These models are mainly focused on payers reimbursing drug manufacturers on the basis of clinical outcomes achieved. Depending on the success and failure of the drugs, prices of them can fall or rise. The companies plan to publicly share analytic insights, findings and recommendations that would help in understanding the use OBRSAs in the health care system.
Optum’s real data assets will facilitate assess to OBRSA models across different patient populations, clinical settings, and therapeutic areas aligned with Merck’s product portfolio.
Zacks Rank and Stocks to Consider
United Health has a Zacks Rank #2 (Buy).You can see Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.